Semaglutide 10 mg Research Peptide Vial
Weight Management
$200.00$70.00
Main Title
Semaglutide 10 mg — GLP-1 Receptor Agonist for Metabolic & Weight Management Research
Full Description
Semaglutide is a synthetic long-acting glucagon-like peptide-1 (GLP-1) receptor agonist with structural modifications that confer extended half-life. It is extensively investigated in preclinical and clinical research for its effects on glycemic control, appetite regulation, body weight reduction, and cardiometabolic parameters in models of obesity and type 2 diabetes.
What It Is
Class: Long-acting GLP-1 receptor agonist (incretin mimetic)
Concept: Mimics the action of endogenous GLP-1 to enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and reduce appetite through central and peripheral mechanisms.
Format: Research-grade synthetic peptide supplied as a lyophilized powder.
Proposed Mechanisms (Preclinical)
GLP-1 Receptor Activation
Binds to GLP-1 receptors on pancreatic β-cells, stimulating glucose-dependent insulin secretion and inhibiting inappropriate glucagon release.
Slows gastric emptying and promotes satiety via vagal and central nervous system pathways.
Appetite & Energy Balance
Acts on hypothalamic neurons to reduce food intake and increase feelings of fullness.
Supports reductions in caloric intake and body weight in obesity models.
Cardiometabolic Effects
Investigated for improvements in lipid profiles, blood pressure, and inflammatory markers in high-risk metabolic models.
Selected Research Highlights
Glycemic Control: Demonstrated robust reductions in HbA1c, fasting glucose, and postprandial glucose excursions in type 2 diabetes research models.
Weight Management: Produced substantial, dose-dependent body weight loss and improvements in body composition in obesity cohorts.
Cardiovascular Outcomes: Studied for beneficial effects on cardiovascular risk factors and major adverse cardiovascular events in high-risk populations.
Gastric & Satiety Effects: Extensively evaluated for delayed gastric emptying and central appetite suppression.
Liver Health: Investigated for reductions in liver fat content and improvements in NAFLD/NASH markers.
Long-Acting Profile: Engineered with fatty acid acylation for once-weekly dosing suitability in research settings.
Chemical & Handling Information
Type: Synthetic 31-amino acid GLP-1 analog
Key Modifications: Two amino acid substitutions and C18 fatty acid diacid acylation for albumin binding and extended half-life
Appearance: White to off-white lyophilized powder
Specifications
Peptide: Semaglutide
Amount: 10 mg per vial
Form: Lyophilized powder
Purity: ≥99% (HPLC) – Certificate of Analysis available per lot
Packaging: Sealed vials suitable for standard laboratory handling
Storage & Stability
Store lyophilized vials in a cool, dry place protected from light.
Refrigeration or freezing of the lyophilized peptide is recommended for extended stability according to laboratory SOPs.
After reconstitution: Store at 2–8 °C for short-term use.
Long-term storage: Aliquot and freeze at –20 °C or below. Avoid repeated freeze-thaw cycles.